Literature DB >> 15528718

Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin.

Cynthia A Sanders1, Rachel R Nieda, Edward P Desmond.   

Abstract

Levofloxacin, the active l-isomer of the quinolone ofloxacin, is now widely accepted for treatment of multidrug-resistant tuberculosis. Because the drug is now widely used, we sought to establish susceptibility test conditions for Mycobacterium tuberculosis against levofloxacin by the traditional reference method, agar proportion (AP), the commonly used BACTEC 460 radiometric system, and the newer BACTEC MGIT 960 method. To determine the stability of levofloxacin in the two newer test systems (BACTEC 460 and BACTEC MGIT 960), media containing subinhibitory levels of levofloxacin were prepared and stored at 4 and 37 degrees C for 14 days. The stored media were inoculated with H37Rv, and the drug activity was compared to freshly prepared media. Results show that levofloxacin is stable over the course of testing. Next, optimum levofloxacin test concentrations were determined for AP, BACTEC 460, and BACTEC MGIT 960 methods. MICs were determined for 32 pan-susceptible isolates of M. tuberculosis obtained from presumably untreated patients and 14 quinolone-resistant isolates. The levofloxacin-resistant strains either were isolated from patients who remained culture-positive despite treatment with a quinolone agent (six strains) or contained known mutations in gyrA (eight strains). Levofloxacin MICs resulted in a bimodal pattern with values for resistant strains consistently higher than those for pan-susceptible strains. Results show that levofloxacin concentrations of 2 microg/ml (BACTEC 460 and BACTEC MGIT 960) and 1 microg/ml (AP) inhibited the growth of all pan-susceptible strains while permitting the growth of all levofloxacin-resistant strains. Confirmatory tests with a subset of pan-susceptible and levofloxacin-resistant isolates validated the selected test concentrations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528718      PMCID: PMC525139          DOI: 10.1128/JCM.42.11.5225-5228.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.

Authors:  G E Pfyffer; D A Bonato; A Ebrahimzadeh; W Gross; J Hotaling; J Kornblum; A Laszlo; G Roberts; M Salfinger; F Wittwer; S Siddiqi
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

2.  Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinical Trials Group 222 Protocol Team.

Authors:  D C Perlman; W M El Sadr; L B Heifets; E T Nelson; J P Matts; K Chirgwin; N Salomon; E E Telzak; O Klein; B N Kreiswirth; J M Musser; R Hafner
Journal:  AIDS       Date:  1997-10       Impact factor: 4.177

3.  Levofloxacin for drug-resistant Mycobacterium tuberculosis.

Authors:  C A Peloquin; S E Berning; G A Huitt; M D Iseman
Journal:  Ann Pharmacother       Date:  1998-02       Impact factor: 3.154

4.  Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to four major antituberculous drugs: comparison with the radiometric BACTEC 460TB method and the agar plate method of proportion.

Authors:  Enrico Tortoli; Marta Benedetti; Alessandra Fontanelli; M Tullia Simonetti
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

Review 5.  The global tuberculosis situation. Progress and problems in the 20th century, prospects for the 21st century.

Authors:  J Peter Cegielski; Daniel P Chin; Marcos A Espinal; Thomas R Frieden; Rodolfo Rodriquez Cruz; Elizabeth A Talbot; Diana E C Weil; Richard Zaleskis; Mario C Raviglione
Journal:  Infect Dis Clin North Am       Date:  2002-03       Impact factor: 5.982

6.  Mycobacterial growth indicator tube for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin.

Authors:  J S Bergmann; G L Woods
Journal:  Diagn Microbiol Infect Dis       Date:  1997-07       Impact factor: 2.803

7.  Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis.

Authors:  C Xu; B N Kreiswirth; S Sreevatsan; J M Musser; K Drlica
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

8.  In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs.

Authors:  M J Ruiz-Serrano; L Alcalá; L Martínez; M Díaz; M Marín; M J González-Abad; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

9.  Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong.

Authors:  Wing Wai Yew; Chi Kuen Chan; Chi Chiu Leung; Chi Hung Chau; Cheuk Ming Tam; Poon Chuen Wong; Joseph Lee
Journal:  Chest       Date:  2003-10       Impact factor: 9.410

10.  In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.

Authors:  B JI; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

View more
  12 in total

Review 1.  Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems.

Authors:  Claudio Piersimoni; Armando Olivieri; Luca Benacchio; Claudio Scarparo
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

2.  Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis.

Authors:  Annika Krüüner; Malcolm D Yates; Francis A Drobniewski
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

3.  Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex.

Authors:  S-Y Grace Lin; Edward Desmond; Donald Bonato; Wendy Gross; Salman Siddiqi
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

4.  Inhibition of the sole type I signal peptidase of Mycobacterium tuberculosis is bactericidal under replicating and nonreplicating conditions.

Authors:  J Ollinger; T O'Malley; J Ahn; J Odingo; T Parish
Journal:  J Bacteriol       Date:  2012-03-16       Impact factor: 3.490

5.  Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.

Authors:  Charles A Peloquin; David Jamil Hadad; Lucilia Pereira Dutra Molino; Moises Palaci; W Henry Boom; Reynaldo Dietze; John L Johnson
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

6.  Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.

Authors:  Sung Jae Shin; Michael T Collins
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

7.  Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance.

Authors:  Rose A Devasia; Amondrea Blackman; Carolyn May; Svetlana Eden; Teresa Smith; Nancy Hooper; Fernanda Maruri; Charles Stratton; Ayumi Shintani; Timothy R Sterling
Journal:  J Antimicrob Chemother       Date:  2009-03-28       Impact factor: 5.790

8.  Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin.

Authors:  Hassan Safi; Brendan Sayers; Manzour H Hazbón; David Alland
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

9.  Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis.

Authors:  Montserrat Garrigó; Lina Marcela Aragón; Fernando Alcaide; Sonia Borrell; Eugenia Cardeñosa; Juan José Galán; Julián Gonzalez-Martín; Nuria Martin-Casabona; Carmen Moreno; Margarita Salvado; Pere Coll
Journal:  J Clin Microbiol       Date:  2007-04-18       Impact factor: 5.948

10.  Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis.

Authors:  Hyejin Kim; Minji Seo; Young Kil Park; Jae-Il Yoo; Yeong Seon Lee; Gyung Tae Chung; Sungweon Ryoo
Journal:  Tuberc Res Treat       Date:  2013-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.